Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
Hemogenyx Pharmaceuticals (OTC:HOPHF) has secured £620,000 in funding through the issuance of convertible loan notes (CLNs) to support its ongoing clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia.
The CLNs were issued at a fixed conversion price of £5.30 per share and are non-interest bearing. They will automatically convert into 116,982 Ordinary Shares following an increase in the Company's headroom restrictions under FCA's Prospectus Rules, expected around November 15, 2025.
Hemogenyx Pharmaceuticals (OTC:HOPHF) ha ottenuto un finanziamento di £620.000 tramite l’emissione di note di prestito convertibili (CLN) per sostenere il trial clinico in corso di HG-CT-1, una terapia CAR-T per leucemia mieloide acuta recidivante o refrattaria.
Le CLN sono state emesse a un prezzo fisso di conversione di £5,30 per azione e non maturano interessi. Si convertiranno automaticamente in 116.982 Azioni Ordinarie al momento dell’aumento delle limitazioni di headroom della Società previste dalle Regole del Prospetto della FCA, atteso intorno al 15 novembre 2025.
Hemogenyx Pharmaceuticals (OTC:HOPHF) ha conseguido £620.000 en financiación mediante la emisión de pagarés convertibles (CLN) para respaldar su ensayo clínico en curso de HG-CT-1, una terapia CAR-T para la leucemia mieloide aguda recidivante o refractaria.
Los CLN se emitieron a un precio fijo de conversión de £5,30 por acción y no devengan intereses. Se convertirán automáticamente en 116.982 Acciones Ordinarias tras el aumento del headroom de la Compañía según las Normas de Prospecto de la FCA, previsto alrededor del 15 de noviembre de 2025.
Hemogenyx Pharmaceuticals (OTC:HOPHF)는 진행 중인 HG-CT-1 임상시험을 지원하기 위해 전환사채(CLN) 발행으로 £620,000의 자금을 확보했습니다. HG-CT-1은 재발성 또는 불응성 급성 골수성 백혈병을 대상으로 한 CAR-T 세포 치료제입니다.
이 CLN은 주당 £5.30의 고정 전환가로 발행되었으며 이자는 발생하지 않습니다. FCA의 증권설명서 규정(Prospectus Rules)에 따른 회사의 헤드룸 제한 상향이 이루어지면, 약 2025년 11월 15일경 자동으로 116,982 보통주로 전환될 예정입니다.
Hemogenyx Pharmaceuticals (OTC:HOPHF) a obtenu un financement de £620 000 via l’émission de billets de prêt convertibles (CLN) afin de soutenir son essai clinique en cours de HG-CT-1, une thérapie CAR-T pour les leucémies myéloïdes aiguës récidivantes ou réfractaires.
Les CLN ont été émises à un prix de conversion fixe de £5,30 par action et ne portent pas d’intérêts. Elles seront automatiquement converties en 116 982 Actions Ordinaires à la suite de l’augmentation du headroom de la Société prévue par les Prospectus Rules de la FCA, attendue vers le 15 novembre 2025.
Hemogenyx Pharmaceuticals (OTC:HOPHF) hat durch die Ausgabe von wandelbaren Darlehen (CLNs) eine Finanzierung in Höhe von £620.000 gesichert, um die laufende klinische Studie zu HG-CT-1 zu unterstützen — einer CAR-T-Zelltherapie für rezidivierte oder refraktäre akute myeloische Leukämie.
Die CLNs wurden zu einem festen Umwandlungspreis von £5,30 je Aktie ohne Zinszahlung ausgegeben. Sie werden voraussichtlich automatisch in 116.982 Stammaktien umgewandelt, sobald die Headroom-Beschränkungen des Unternehmens gemäß den Prospectus Rules der FCA erhöht werden, voraussichtlich um den 15. November 2025.
- Secured £620,000 in additional funding for clinical trial development
- Non-interest bearing CLNs minimize debt service costs
- Fixed conversion price at £5.30 provides price stability
- Funding demonstrates investor confidence in HG-CT-1 clinical trial progress
- Future dilution of existing shareholders upon CLN conversion
- Relatively small funding amount may indicate limited investor interest
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Issue of convertible loan notes to raise
LONDON, GB / ACCESS Newswire / September 1, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised
Convertible Loan Notes
To support the clinical trial, the Company has raised
The CLNs, which are non-interest bearing, will automatically convert following an increase in the Company's headroom restrictions under the FCA's Prospectus Rules, allowing for the issuance of conversion shares without requiring an approved prospectus. This conversion is expected to take place on or after 15 November 2025.
Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, commented:
"We are very encouraged by the progress of our Phase I clinical trial of HG-CT-1, and we are grateful for the continued support of our investors. Their participation in this funding reflects confidence in our strategy and long-term vision. These CLNs strengthen our balance sheet, extend our financial runway, and enable us to maintain momentum in the clinical development of HG-CT-1 for patients with relapsed or refractory acute myeloid leukemia."
Application for Admission
The Company will apply for the admission of the 116,982 Ordinary Shares, issued to subscribers upon the conversion of the CLNs, to trading on the London Stock Exchange. Admission is expected to become effective after 15 November 2025.
Upon admission, the new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares and will be entitled to receive all future dividends and distributions declared, paid, or made on the Company's ordinary share capital.
UK Market Abuse Regulation (UK MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc | ||
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | ||
Peter Redmond, Director | ||
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 | |
Matthew Johnson, Vadim Alexandre, Adam Cowl | ||
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 | |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City .
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
How much funding did Hemogenyx Pharmaceuticals (HOPHF) raise through convertible loan notes in September 2025?
What is the conversion price for Hemogenyx's September 2025 convertible loan notes?
When will Hemogenyx's September 2025 convertible loan notes convert to shares?
What will Hemogenyx use the September 2025 convertible loan note proceeds for?
How many new shares will be issued when Hemogenyx's convertible notes convert?
